

Trade names of stationary phases found suitable in performing chromatographic tests described in Ph.Int.

08.Jun.22



The selectivity of chromatographic tests may not only depend on the parameters mentioned in the methods' descriptions but also on the material of the used stationary phases. The International Pharmacopoeia thus provides a list of trade names of the stationary phases that were found to be suitable when the monographs were being developed. This information is provided solely for the convenience of users. The mentioned suppliers are neither endorsed nor recommended by The International Pharmacopoeia nor does the information imply any preference to other stationary phases of a similar nature which are not mentioned. The user should also be aware of the fact that some stationary phases can show significant batch-to-batch variations. The list will be continued.

Monograph	Version	Test	Trade name of stationary phases found suitable
Aciclovir	2014-01	Guanine and related substances A.1	Merck cellulose F plate
Aciclovir	2014-01	Guanine and related substances B	Dionex C18 or Shiseido MG C18
Aciclovir sodium for injection	2014-01	Guanine and related substances A.1	Merck cellulose F
Aciclovir sodium for injection	2014-01	Guanine and related substances B	Dionex C18 or Shiseido MG C18
Aciclovir sodium for injection	2014-01	Assay A	Dionex C18 or Shiseido MG C18
Aciclovir tablets	2014-01	Guanine and related substances A	Merck cellulose F
Aciclovir tablets	2014-01	Assay A	Dionex C18 or Shiseido MG C18
Albendazole	2025-01	Related substances;	Symmetry C18
Albendazole chewable tablet	2025-01	Related substances; Assay	Nova Pak C18
Albendazole chewable tablets	2014-01	Assay A	Inertsil ODS-SP
Albendazole tablet	2025-01	Related substances; Assay	Nova Pak C18
Amoxicillin and clavulanic acid tablets	2018-01	Related substances, Assay	Shim-pack CL-ODS
Amoxicillin trihydrate	2018-01	Related substances, Assay	Agilent Xbridge C18
Atazanavir capsules	2015-01	Related substances; Assay	Nucleosil 100-10 CN
Atazanavir sulfate	2015-01	Related substances	Inertsil C8
Benzathine benzylpenicillin powder for injection	2025-02	Related substances, Assay	YMC-Pack ODS-A or Waters Atlantis T3 column
Benzathine benzylpenicillin tetrahydrate	2025-02	Related substances, Assay	YMC-Pack ODS-A or Waters Atlantis T3 column
Carbamazepine	2016-01	Test for related substances, Assay	Nucleosil 100-10 CN
Carbamazepine oral suspension	2016-01	Test for related substances, Assay	Nucleosil 100-10 CN
Carbamazepine tablets	2016-01	Test for related substances, Assay	Nucleosil 100-10 CN
Ceftriaxone for injection	2017-01	Assay	Lux Cellulose-4
Ceftriaxone sodium	2017-01	Assay	Lux Cellulose-4
Chlorhexidine digluconate solution	2017-01	Test for related substances	Luna C18
Ciprofloxacin hydrochloride	2020-01	Related substances, Assay	Nucleosil 120-C18, LiChrospher 100 RP 18, Prodigy ODS-3
Ciprofloxacin tablets	2020-01	Related substances, Assay	Nucleosil 120-C18, LiChrospher 100 RP 18, Prodigy ODS-3
Clavulanate potassium	2018-01	Related substances	Waters Atlantis T3
Clavulanate potassium	2018-01	Assay	Zorbax eclipse XDB-C18
Clindamycin hydrochloride	2016-01	Related substances; Assay	Hypersil BDS
Clindamycin hydrochloride capsules	2016-01	Related substances; Assay	Hypersil BDS
Clindamycin palmitate hydrochloride	2018-01	Related substances	Zorbax Elipse XDB- C8
Clindamycin palmitate hydrochloride	2018-01	Assay	Waters Symmetry C8
Clindamycin palmitate powder for oral solution	2018-01	Related substances	Zorbax Elipse XDB- C8
Clindamycin phosphate injection	2017-01	Test for related substances, Assay	Symmetry C18
Clindamycin phosphate injection	2017-01	Test for related substances, Assay	Symmetry C18
Clofazimine	2025-02	Related substances	Licrosphere C8 or Nucleosil C8
Daclatasvir dihydrochloride	2019-01	Impurity A	Lux i-Cellulose-5 or Chiralpak IC-3
Daclatasvir dihydrochloride	2019-01	Related substances, Assay	XBridge BEH C18 or Xselect CSH C18
Daclatasvir tablets	2019-01	Related substances, Assay	XBridge BEH C18 or Xselect CSH C18
Darunavir	2025-02	Ethanol content	Agilent J&W DB-624
Darunavir	2025-02	Related substances, Assay	Zorbax-SB-C18
Darunavir oral suspension	2025-02	Related substances, Assay	Zorbax-SB-C18

Darunavir tablets	2025-02	Related substances, Assay	Zorbax-SB-C18
Dextromethorphan hydrobromide	2016-01	Impurity E (Levomethorphan)	Chiralcel OJ-H
Dextromethorphan hydrobromide	2016-01	Related substances	Waters Symmetry C18
Dextromethorphan oral solution	2016-01	Related substances; Assay	Shiseido ACR or Phenomenex Luna
Dolutegravir dispersible tablets	2022-01	Test for related substances, Assay	ACE 5 C18-PFP
Dolutegravir sodium	2022-01	Impurity A, impurity B and G	Lux Cellulose-4
Dolutegravir sodium	2022-01	Test for related substances, Assay	ACE 5 C18-PFP
Dolutegravir tablets	2022-01	Test for related substances, Assay	ACE 5 C18-PFP
Efavirenz	2015-01	Related substances	Zorbax SB CN
Efavirenz	2025-01	Test for impurity K	Lux Amylose-1 or Chiralpak AD
Efavirenz	2025-01	Related substances, procedure 1; Assay	Zorbax SB-CN
Efavirenz	2025-01	Related substances, procedure 2 (impurities Q, R and S)	Hypersil BDS C18 or Symmetry C18
Estradiol valerate	2019-01	Related substances, Assay	Inertsil ODS2, Spherisorb ODS2, Hypersil ODS or Kinetex C18
Estradiol valerate and norethisterone enantate	2025-01	Related substances, Assay	Zorbax SB-18
Ethambutol dihydrochloride	2025-02	Related substances	Luna C18(2)
Ethinyl estradiol	2016-01	Assay A	Agilent SB-C18
Ethinylestradiol	2019-01	Related substances, Assay	YMC Pack Pro C4
Fluconazole capsules	2015-01	Assay	Capcell Pak C18 MGII
Fluconazole injection	2015-01	Assay	Capcell Pak C18 MGII
Flucytosine	2016-01	Related substances B	Zorbax SB-C18
Flucytosine intravenous infusion	2016-01	Related substances	Capcell Pak C18 MGII
Isoniazid	2025-01	Impurity E	Inertsil ODS-3V or Symmetry C18
Isoniazid	2025-01	Related substances	Agilent Eclipse Plus C18
Isoniazid tablets	2025-01	Impurity E	Inertsil ODS-3V or Symmetry C18
Isoniazid tablets	2025-01	Related substances, Assay (Method A)	Agilent Eclipse Plus C18
Ethinylestradiol	2025-01	Impurity E	Inertsil ODS-3V or Symmetry C18
Ivermectin	2019-01	Related substances, Assay	Agilent PoroShell, Zorbax SB C ₁₈
Ivermectin tablets	2019-01	Related substances, Assay	Agilent PoroShell, Zorbax SB C18
Lamivudine	2022-01	Related substances	Hypersil BDS
Lamivudine	2022-01	Impurity D (lamivudine enantiomer)	Astec Cyclobond I 2000 SP or I 2000-RSP
Lamivudine and tenofovir disoproxil tablets	2025-01	Related substances	Inertsil ODS-3v
Lamivudine and tenofovir disoproxil tablets	2025-01	Assay	EclipseXDB C8
Lamivudine oral solution	2022-01	Related substances	Zorbax RX-C8
Lamivudine, dolutegravir and tenofovir disoproxil fumarate tablets	2022-01	Lamivudine- and tenofovir disoproxil-related substances	Inertsil ODS-3v
Lamivudine, dolutegravir and tenofovir disoproxil fumarate tablets	2022-01	Dolutegravir-related substances	ACE 5 C18-PFP
Lamivudine, dolutegravir and tenofovir disoproxil fumarate tablets	2022-01	Assay	EclipseXDB C8
Levofloxacin hemihydrate	2020-01	Related substances	Inertsil ODS-2 or ODS-3
Levofloxacin tablets	2020-01	Related substances, Assay	Inertsil ODS-2 or ODS-3
Levomethorphan limit test for dextromethorphan containing finished pharmaceutical product	2016-01		Chiralcel OJ-H
Levonorgestrel	2016-01	Related substances A	Symmetry Shield RP8
Levonorgestrel	2016-01	Related substances B	Pack ODS-AQ (YMC)
Levonorgestrel tablets	2014-01	Related substances; Assay	Spherisorb ODS 2
Linezolid	2025-01	Test for impurity E (linezolid R-isomer)	Phenomenex Lux Amylose-1 or Chiralpak IA
Linezolid	2025-01	Related substances	Zorbax EclipseXDB C8
Linezolid tablets	2025-01	Related substances, Assay	Zorbax EclipseXDB C8
Mebendazole	2017-01	Test for related substances,	HYPERSIL BDS C18
Mebendazole chewable tablets	2017-01	Test for related substances, Assay	HYPERSIL BDS C18
Mebendazole tablets	2017-01	Test for related substances, Assay	HYPERSIL BDS C ₁₈
Medroxyprogesterone acetate	2014-01	Impurity F	Ultimate XB-C18
Medroxyprogesterone acetate	2014-01	Related substances	Alltima C18
Mefloquine hydrochloride	2015-01	Related substances	Luna

Mefloquine tablets	2015-01	Related substances, Assay	Luna
Methylthionium chloride	2017-01	Test for related substances, Assay	X-Bridge Phenyl or Phenomenex Luna Phenyl-Hexyl
Methylthionium injection	2017-01	Test for related substances, Assay	X-Bridge Phenyl or Phenomenex Luna Phenyl-Hexyl
Mifepristone	2025-02	Related substances	Luna C18(2) or Nucleosil C18
Mifepristone tablets	2025-02	Related substances	Luna C18(2) or Nucleosil C18
Misoprostol	2016-01	Diastereoisomers	Xbridge HILIC
Misoprostol	2016-01	Test for related substances, Assay	Ascentis Express C18
Misoprostol dispersion	2016-01	Diastereoisomers	Xbridge HILIC
Misoprostol dispersion	2016-01	Test for related substances, Assay	Ascentis Express C18
Misoprostol tablets	2016-01	Test for related substances, Assay, Uniformity of Content	Ascentis Express C18
Molnupiravir	2025-01	Related substances	Kromasil 100-5 Phenyl
Molnupiravir	2025-01	Assay	Kinetex Biphenyl 100 A
Molnupiravir capsules	2025-01	Related substances	Kromasil 100-5 Phenyl
Molnupiravir capsules	2025-01	Assay	Kinetex Biphenyl 100 A
Moxifloxacin hydrochloride	2019-01	Impurity G	ACE 3 C18
Moxifloxacin hydrochloride	2019-01	Related substances, Assay A	Inertsil Ph, Zorbax Eclipse XDB-Phenyl
Moxifloxacin tablets	2019-01	Related substances, Assay	Inertsil Ph, Zorbax Eclipse XDB-Phenyl
Nirmatrelvir	2025-01	Related substances, Assay	Zorbax RRHD SB-Phenyl
Nirmatrelvir tablets	2025-01	Related substances, Assay	Zorbax RRHD SB-Phenyl
Nirmatrelvir tablets	2025-01	Dissolution	Kromasil 100 C18
Norethisterone	2016-01	Related substances	Agilent ZORBAX Eclipse XDB-C8
Norethisterone enantate	2022-01	Related substances	Zorbax Bonus RP
Norethisterone enantate injection	2022-01	Related substances	Luna C18(2)
Norethisterone tablets	2016-01	Related substances	Zorbax eclipse XDB-C18
Norethisterone tablets	2016-01	Assay	JADE-PAKODS-AQ
Pyrantel chewable tablets	2015-01	Related substances, Assay	Luna C18(2)
Pyrantel embonate	2015-01	Related substances	Shim-pack HRC-SIL
Pyrantel tablets	2015-01	Related substances, Assay	Shim-pack HRC-SIL
Pyrimethamine	2020-01	Related substances	Agilent Zorbax Eclipse XDB-C18
Pyrimethamine tablets	2020-01	Related substances, Assay	Agilent Zorbax Eclipse XDB-C18
Remdesivir	2022-01	Related substances	YMC Hydrosphere
Remdesivir	2022-01	Assay	YMC-Pack ODS-A or Inertsil ODS-3V
Remdesivir intravenous infusion	2022-01	Related substances	YMC Hydrosphere
Remdesivir intravenous infusion	2022-01	Assay	YMC-Pack ODS-A
Rifampicin	2025-01	Related substances	Lichrosorb RP8 or Nucleosil C8
Sofosbuvir	2020-01	Related substances, Assay	XSelect C18
Sofosbuvir tablets	2020-01	Related substances, Assay	XSelect C18
Sulfamethoxazole and trimethoprim intravenous infusion	2014-01	Assay A	Hypersil BDS C18
Sulfamethoxazole and trimethoprim oral suspension	2014-01	Assay A	Hypersil BDS C18
Tenofovir disoproxil fumarate	2025-01	Impurity G	Lux Amylose 1
Tenofovir disoproxil fumarate	2025-01	Related substances	Inertsil ODS-3v
Tenofovir disoproxil tablets	2025-01	Related substances, Assay	Inertsil ODS-3v
Test for 1-Methyl-4-nitroso piperazine (MeNP) in Rifampicin active pharmaceutical ingred	2025-01	Test for MeNP	Phenomenex Luna Phenyl-Hexyl
Tetracycline hydrochloride	2019-01	Related substances, Assay	Prodigy ODS-3 column
Ulipiristal acetate	2022-01	Related substances, Assay	Hichrom Apex ODS
Ulipiristal acetate table	2022-01	Related substances, Assay	Hichrom Apex ODS
Zidovudine	2025-02	Related substances A, Assay	Luna C18(2) or Spherisorb ODS-2
Zidovudine	2025-02	Related substances B	Hypersil BDS-C18
Zidovudine capsules	2025-02	Related substances A, Assay	Luna C18(2) or Spherisorb ODS-2

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Trade names of stationary phases found suitable in performing chromatographic tests described in Ph.Int. Geneva: World Health Organization; 2026 (WHO/HSD/HPS/PSN/2026.1). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <https://iris.who.int/>.

Sales, rights and licensing. To purchase WHO publications, see <https://www.who.int/publications/book-orders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for